uploads///Bridion and Primaxin

How Merck’s Bridion and Primaxin Performed in 2017

By

Mar. 16 2018, Updated 9:00 a.m. ET

Bridion’s revenue trends

In 4Q17, Merck’s (MRK) Bridion reported revenues of $209 million, which reflected a ~50% rise on a YoY (year-over-year) basis and a ~13% rise on a QoQ (quarter-over-quarter) basis. In 4Q17, in the US and in international markets, Bridion reported revenues of $76 million and $132 million, respectively, compared with $36 million and $104 million in 4Q16.

In fiscal 2017, Bridion reported revenues of $704 million, compared with $482 million in 2016, which is ~46% higher YoY. In 2017, in the US and in international markets, Bridion generated revenues of $239 million and $465 million, respectively, compared with $77 million and $405 million in 2016.

Bridion’s US patent will only expire after 2026, while in the European Union and Japan, Bridion’s patents will expire in 2023 and 2024, respectively. Bridion is used for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in patients undergoing surgery.

Strong global demand, along with high demand in the US, primarily attributed to the high revenue growth of the drug in 2017. Merck anticipates steady growth for Bridion in 2018.

Article continues below advertisement

Primaxin’s revenue trends

In 4Q17, Primaxin generated revenues of $74 million, which is ~12% higher on a YoY basis and a 1% rise on a QoQ (quarter-over-quarter) basis. In 2017, Primaxin reported revenues of $280 million, compared with $297 million in 2016, which was 6% lower YoY.

In 2017, in the US and in international markets, Primaxin reported revenues of $10 million and $270 million, respectively, compared with $4 million and $293 million in 2016.

Primaxin is a combination drug used for the treatment of various bacterial infections. Primaxin is primarily used for the treatment of lower respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and skin structure infections, and polymicrobial infections.

Notably, in 4Q17, Merck’s peers in the hospital acute care products market include Pfizer (PFE), Teva Pharmaceuticals (TEVA), and GlaxoSmithKline (GSK) reported revenues of $13.7 billion, $5.5 billion, and $10.1 billion, respectively.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.